Androgen Receptor Inhibitors in Patients With Nonmetastatic Castration-Resistant Prostate Cancer

恩扎鲁胺 医学 中止 前列腺癌 耐受性 内科学 队列 雄激素受体 肿瘤科 不利影响 癌症
作者
Daniel J. George,Alicia K. Morgans,Niculae Constantinovici,Nasreen Khan,Javeed Khan,Guifang Chen,Vlasta Hlebec,Neal D. Shore
出处
期刊:JAMA network open [American Medical Association]
卷期号:7 (8): e2429783-e2429783
标识
DOI:10.1001/jamanetworkopen.2024.29783
摘要

Importance Novel androgen receptor inhibitors (ARIs; darolutamide, enzalutamide, and apalutamide) are standard-of-care treatments for nonmetastatic castration-resistant prostate cancer (nmCRPC). However, there are sparse data comparing their clinical use and tolerability. Objective To compare clinical use and outcomes for darolutamide, enzalutamide, and apalutamide in patients with nmCRPC. Design, Setting, and Participants This retrospective cohort study reviewed electronic medical records from the Precision Point Specialty network of US urology practices. Eligible patients had nmCRPC and no prior novel hormonal therapy and initiated novel ARI treatment between August 1, 2019, and March 31, 2022. Data were analyzed from February 1, 2019, to December 31, 2022. Exposures Patients were prescribed darolutamide, enzalutamide, or apalutamide as their first novel ARI for nmCRPC. Main Outcomes and Measures The main outcome was a composite of 2 end points, treatment discontinuation and progression to metastatic CRPC (mCRPC), whichever occurred first. Both end points were also assessed separately. Results All 870 patients meeting eligibility criteria were included (362 receiving darolutamide [41.6%]; 382, enzalutamide [43.9%]; 126, apalutamide [14.5%]); mean (SD) age was 78.8 (8.7) years. Self-reported race was Black or African American in 187 patients (21.5%), White in 585 (67.2%), and other or unknown in 98 (11.3%). The darolutamide cohort had lower proportions of patients with a composite end point event (134 [37.0%] vs 201 [52.6%] for enzalutamide and 66 [52.4%] for apalutamide), discontinuation (110 [30.4%] for darolutamide vs 156 [40.8%] for enzalutamide and 58 [46.0%] for apalutamide), and progression to mCRPC (64 [17.7%] for darolutamide vs 108 [28.3%] for enzalutamide and 35 [27.8%] for apalutamide) during the study period. After adjusting for baseline covariates, patients receiving darolutamide had a lower risk of a composite end point event compared with enzalutamide (risk reduction, 33.8%; hazard ratio [HR], 0.66 [95% CI, 0.53-0.84]) and apalutamide (risk reduction, 35.1%; HR, 0.65 [95% CI, 0.48-0.88]). Similarly, patients receiving darolutamide had a lower risk of discontinuation compared with enzalutamide (risk reduction, 27.4%; HR, 0.73 [95% CI, 0.56-0.94]) and apalutamide (risk reduction, 39.1%; HR, 0.61 [95% CI, 0.44-0.85]) and a lower risk of progression to mCRPC compared with enzalutamide (risk reduction, 40.6%; HR, 0.59 [95% CI, 0.43-0.82]) and apalutamide (risk reduction, 35.3%; HR, 0.65 [95% CI, 0.42-0.99]). There was no difference between enzalutamide and apalutamide treatment across outcomes. Conclusions and Relevance In this large cohort study of patients with nmCRPC treated with novel ARIs, results suggest better tolerability for darolutamide compared with enzalutamide and apalutamide, which may be associated with a clinical effectiveness advantage. Comparative clinical studies are needed to guide treatment decisions in the absence of head-to-head clinical trials.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Code_king发布了新的文献求助10
刚刚
刚刚
pmh完成签到,获得积分10
刚刚
科研通AI6.4的应助被srkb采纳,获得10
1秒前
小二郎的应助被Foremelon采纳,获得10
1秒前
1秒前
初景的应助被帅气皮皮虾采纳,获得20
1秒前
1秒前
1秒前
wait完成签到 ,获得积分10
1秒前
Code_king发布了新的文献求助10
1秒前
大模型的应助被顺顺利利采纳,获得10
1秒前
郁离完成签到 ,获得积分10
2秒前
无花果的应助被UnprofessionalX采纳,获得10
2秒前
Code_king发布了新的文献求助10
2秒前
2秒前
笛子发布了新的文献求助10
2秒前
hua发布了新的文献求助10
2秒前
2秒前
Code_king发布了新的文献求助10
2秒前
2秒前
Code_king发布了新的文献求助10
2秒前
Code_king发布了新的文献求助10
3秒前
Code_king发布了新的文献求助10
3秒前
麦季完成签到,获得积分20
3秒前
MZX完成签到,获得积分10
3秒前
Code_king发布了新的文献求助10
4秒前
曼容完成签到,获得积分20
4秒前
4秒前
Roseanne完成签到,获得积分10
4秒前
4秒前
HI完成签到,获得积分10
4秒前
Youdge的应助被袁气奶豆采纳,获得20
4秒前
lxm发布了新的文献求助10
4秒前
5秒前
5秒前
大橙子发布了新的文献求助10
5秒前
Code_king发布了新的文献求助10
5秒前
6秒前
脑洞疼的应助被琳琳林采纳,获得10
6秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8176102
求助须知:如何正确求助?哪些是违规求助? 9567588
关于积分的说明 21793477
捐赠科研通 7770603
什么是DOI,文献DOI怎么找? 3431969
关于科研通互助平台的介绍 2556294
邀请新用户注册赠送积分活动 2477522